Please assess the completion status of the following clinical trial:

Trial Title: Cerebrospinal Fluid Pharmacokinetics of Daptomycin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Adults with suspected EVD related meningitis or ventriculitis who already have an external ventricular drain placed, as part of standard clinical care for CSF drainage, and whose clinicians plan to start antibiotics. There should be a clinical indication for the EVD to be in place for ≥ 72 hrs. An intravenous line which can be accessed for blood draws should be present.~Exclusion Criteria:~Age less than 18 years of age Patient is a woman who is pregnant or lactating Allergies or prior adverse reactions to daptomycin, which would preclude its use.~Elevated CK levels (\>500). Inability to obtain informed consent or get proxy consent. Patients on CRRT (continuous renal replacement therapies) or on dialysis Patients with an estimated CrCl \<30 cc/min as estimated by MDRD at base line. Patients with a BMI \>30 Any medical condition leading to a life expectancy of \< 48 hours, as determined by the clinician.~Patient who have received a dose of daptomycin in the last 7 days. Patients is participating in other studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- open label (Type: OTHER): patients meeting entry criteria enrolled and pk samples obtained around dosing of daptomycin

Based on this trial design, predict the completion outcome and termination type (if applicable).